BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that Dr. David Feigal has resigned as a member of the Company’s Board of Directors. Dr. Feigal cited a crush of other commitments as the reason for his resignation. Dr. Lars Ekman, Amarin’s Lead Independent Director said, “On behalf of everyone at Amarin, I thank David for his contributions to the Company, including his review of our NDA for AMR101 prior to it being submitted in September for FDA review. We wish him well in his many endeavors.” Earlier today Amarin announced that its NDA, which seeks regulatory approval for the use of AMR101 in the treatment of patients with very high triglyceride levels (>=500 mg/dL), has been accepted for filing by the U.S. Food and Drug Administration (FDA) for review.
